ACell’s MatriStem technology is designed for surgical soft tissue repair and complex wound management. The new contract with Novation will make MatriStem available to an additional 100,000 healthcare providers.
ACell is a regenerative medicine company focused on the development, manufacturing and commercialization of tissue repair products.
More Articles on Supply Chain:
Reducing Supply Chain Costs
First Navio Unicondylar Knee Replacement Performed in France
Abrams Royal Pharmacy Issues Voluntary Recall on All Unexpired Sterile Products
